After an initial 60 weeks on Zepbound at the MTD, participants either continued on the MTD, reduced the dose to 5 mg, or received a placebo
This cell swelling is not cosmetic
In 2017, the Food and Drug Administration approved a new iteration, Ozempic (semaglutide), as a T2D treatment
The STEP 1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo [7]
The FDA has approved several GLP-1 receptor agonists for type 2 diabetes management and, in some cases, chronic weight management
The most important thing to understand: the semaglutide molecule itself is colorless when dissolved in solution